Drug intelligence / Profile preview

Cobramine

Development stage: Unknown
Lead developer: Celtic Biotech
Modality: Peptides

Overview

CB-6 (Cobramine) is a peptide-based protein kinase C (PKC) inhibitor developed by Celtic Biotech for the treatment of chronic kidney disease (CKD). Derived from snake venom research, CB-6 targets PKC isoforms that are implicated in the progression of renal damage, including fibrosis and inflammatory responses. By inhibiting PKC signaling, the drug aims to slow the decline of kidney function in patients with CKD. It is currently in the early stages of clinical development, identified as Phase Ib ready.

Other names: Cobramine

Targets

PKC (Protein kinase C family)

Beyond the preview

Go deeper on Cobramine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cobramine.

Explore the full profile